2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Lung Neoplasms
10
Adenocarcinoma of Lung
7
Neoplasms
6
Neoplasm Metastasis
5
Melanoma
3
Glioblastoma
3
Carcinoma
3
cMET-dysregulated Advanced Solid Tumors
2
Sarcoma
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Gliosarcoma
2
Colorectal Neoplasms
2
cMET Dysegulation Advanced Solid Tumors
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Noonan Syndrome 6
1
Neuroblastoma
1
Malignant Non-small Cell Neoplasm of Lung Stage IV
1
Lymphoproliferative Disorders
1
Liver Neoplasms
1
Laryngeal Diseases
1
Kidney Neoplasms
1
Hepatic Impairment
1
Glioma
1
EGFR-mutant Non-small Cell Lung Cancer
1
Interventions
Oxaliplatin
295
Capecitabine
209
Fluorouracil
183
Cisplatin
172
Docetaxel
140
S 1 (combination)
135
Paclitaxel
128
Leucovorin
117
Irinotecan
110
pembrolizumab
104
Trastuzumab
75
Nivolumab
59
apatinib
57
Drug Therapy
52
sintilimab
46
Surgical Procedures, Operative
45
Ramucirumab
40
Radiotherapy
40
Bevacizumab
37
Hyperthermic Intraperitoneal Chemotherapy
34
Epirubicin
32
titanium silicide
31
tislelizumab
31
Carboplatin
31
Gastrectomy
28
Cyclophosphamide
27
XELOX
25
Tegafur
24
Folfox protocol
23
Albumin-Bound Paclitaxel
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
capmatinib
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled